EP4324526A3 - Immunogenic anti-inflammatory compositions - Google Patents

Immunogenic anti-inflammatory compositions Download PDF

Info

Publication number
EP4324526A3
EP4324526A3 EP23205355.3A EP23205355A EP4324526A3 EP 4324526 A3 EP4324526 A3 EP 4324526A3 EP 23205355 A EP23205355 A EP 23205355A EP 4324526 A3 EP4324526 A3 EP 4324526A3
Authority
EP
European Patent Office
Prior art keywords
tissue
inflammatory
specific organ
composition
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23205355.3A
Other languages
German (de)
French (fr)
Other versions
EP4324526A2 (en
Inventor
Harold David Gunn
Salim Dhanji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qu Biologics Inc
Original Assignee
Qu Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/843,296 external-priority patent/US8501198B2/en
Priority claimed from US13/019,208 external-priority patent/US9107864B2/en
Application filed by Qu Biologics Inc filed Critical Qu Biologics Inc
Publication of EP4324526A2 publication Critical patent/EP4324526A2/en
Publication of EP4324526A3 publication Critical patent/EP4324526A3/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0002Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49Breast
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/54Pancreas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/58Prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens
    • A61K39/008Leishmania antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0258Escherichia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0266Klebsiella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0275Salmonella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/05Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/102Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/104Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045Moraxella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4615Dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/462Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622Antigen presenting cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

The invention provides methods of formulating an anti-inflammatory composition for treating inflammatory conditions in a specific organ or tissue. The method involves selecting at least one pathogen that is pathogenic in the specific organ or tissue; producing an antigenic composition comprising antigenic determinants that together are specific for the pathogen; and formulating the antigenic composition for administration as an anti-inflammatory composition capable of eliciting an anti-inflammatory response in the specific organ or tissue, wherein the condition characterized by inflammation is not a cancer. In embodiments of the invention, a cancer is situated in the specific organ or tissue.
EP23205355.3A 2010-07-26 2011-07-26 Immunogenic anti-inflammatory compositions Pending EP4324526A3 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US12/843,296 US8501198B2 (en) 2004-06-07 2010-07-26 Tissue targeted antigenic activation of the immune response to treat cancers
US41137110P 2010-11-08 2010-11-08
US13/019,208 US9107864B2 (en) 2004-06-07 2011-02-01 Tissue targeted antigenic activation of the immune response to treat cancers
US201161500836P 2011-06-24 2011-06-24
PCT/CA2011/000851 WO2012012874A1 (en) 2010-07-26 2011-07-26 Immunogenic anti-inflammatory compositions
EP11811677.1A EP2598165B1 (en) 2010-07-26 2011-07-26 Immunogenic anti-inflammatory compositions
EP17163849.7A EP3235506B1 (en) 2010-07-26 2011-07-26 Immunogenic anti-inflammatory compositions

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
EP17163849.7A Division EP3235506B1 (en) 2010-07-26 2011-07-26 Immunogenic anti-inflammatory compositions
EP17163849.7A Division-Into EP3235506B1 (en) 2010-07-26 2011-07-26 Immunogenic anti-inflammatory compositions
EP11811677.1A Division EP2598165B1 (en) 2010-07-26 2011-07-26 Immunogenic anti-inflammatory compositions

Publications (2)

Publication Number Publication Date
EP4324526A2 EP4324526A2 (en) 2024-02-21
EP4324526A3 true EP4324526A3 (en) 2024-05-22

Family

ID=45529307

Family Applications (3)

Application Number Title Priority Date Filing Date
EP23205355.3A Pending EP4324526A3 (en) 2010-07-26 2011-07-26 Immunogenic anti-inflammatory compositions
EP11811677.1A Active EP2598165B1 (en) 2010-07-26 2011-07-26 Immunogenic anti-inflammatory compositions
EP17163849.7A Active EP3235506B1 (en) 2010-07-26 2011-07-26 Immunogenic anti-inflammatory compositions

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP11811677.1A Active EP2598165B1 (en) 2010-07-26 2011-07-26 Immunogenic anti-inflammatory compositions
EP17163849.7A Active EP3235506B1 (en) 2010-07-26 2011-07-26 Immunogenic anti-inflammatory compositions

Country Status (17)

Country Link
US (1) US10130692B2 (en)
EP (3) EP4324526A3 (en)
JP (5) JP5923501B2 (en)
KR (2) KR102157718B1 (en)
CN (2) CN103140238B (en)
AU (3) AU2016238866B2 (en)
CA (1) CA2804709A1 (en)
DK (1) DK2598165T3 (en)
ES (2) ES2971415T3 (en)
IL (2) IL224048B (en)
MX (1) MX345240B (en)
MY (1) MY188328A (en)
NZ (2) NZ606490A (en)
PL (1) PL2598165T3 (en)
RU (2) RU2722357C2 (en)
SG (2) SG187201A1 (en)
WO (1) WO2012012874A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
KR102157718B1 (en) 2010-07-26 2020-09-18 큐 바이올로직스 인코포레이티드 Immunogenic anti-inflammatory compositions
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
US10988516B2 (en) * 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
US9546361B2 (en) * 2012-10-12 2017-01-17 Lehigh University Thermally stable enzymes, compositions thereof and methods of using same
WO2014160266A1 (en) * 2013-03-14 2014-10-02 Coronado Biosciences, Inc. Treatment of type i diabetes mellitus using helminthic parasite preparations
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
EP3065771B1 (en) 2013-11-04 2019-03-20 UTI Limited Partnership Methods and compositions for sustained immunotherapy
US10251946B2 (en) 2014-05-02 2019-04-09 Qu Biologics Inc. Anti-microbial immunomodulation
WO2016075687A2 (en) * 2014-11-10 2016-05-19 Yissum Research Develoment Company Of The Hebrew University Of Jerusalem Ltd. Attenuated or inactivated pathogenic escherichia coli for treating urogenital cancer
ME02997B (en) 2014-12-23 2018-10-20 4D Pharma Res Ltd A bacteroides thetaiotaomicron strain and its use in reducing inflammation
WO2016102951A1 (en) 2014-12-23 2016-06-30 4D Pharma Research Limited Pirin polypeptide and immune modulation
US12011480B2 (en) 2015-05-06 2024-06-18 Uti Limited Partnership Nanoparticle compositions for sustained therapy
CN115364122A (en) 2015-06-15 2022-11-22 4D制药研究有限公司 Compositions comprising bacterial strains
MA41010B1 (en) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41060B1 (en) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprising bacterial strains
MD3307288T2 (en) 2015-06-15 2019-12-31 4D Pharma Res Ltd Compositions comprising bacterial strains
PL3206700T3 (en) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprising bacterial strains
CN105176882B (en) * 2015-10-17 2018-09-21 福清市默克兽医院 A kind of ox morganella morganii arthritis inactivated vaccine and preparation method thereof
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
EA034677B1 (en) 2015-11-20 2020-03-05 4Д Фарма Рисёрч Лимитед Compositions for treating or preventing cancer comprising enterococcus gallinarum strain
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
DK3313423T3 (en) 2016-03-04 2019-05-20 4D Pharma Plc COMPOSITIONS INCLUDING BACTERIAL BLAUTIA STAMPS FOR TREATMENT OF VISCERAL HYPERSENSITIVITY
CN109414461A (en) 2016-04-26 2019-03-01 曲生物制品公司 Therapeutically trigger the innate immune response in target tissue
CN105797153A (en) * 2016-05-02 2016-07-27 浙江农林大学 Veterinary vaccine immunologic adjuvant as well as preparation and application method thereof
CN106011007A (en) * 2016-06-06 2016-10-12 余国华 Combined drug-resistant bacterium immunoreactive protein, and preparation method and application thereof
TWI802545B (en) 2016-07-13 2023-05-21 英商4D製藥有限公司 Compositions comprising bacterial strains
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
US10596206B1 (en) * 2017-03-14 2020-03-24 Cornell University Probiotic compositions and methods of use
WO2018217764A1 (en) * 2017-05-22 2018-11-29 Kansas State University Research Foundation Microbiome transplantation
LT3630136T (en) 2017-05-22 2021-06-10 4D Pharma Research Limited Compositions comprising bacterial strains
WO2018215782A1 (en) 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strain
IL283973B (en) 2017-06-14 2022-08-01 4D Pharma Res Ltd Compositions comprising bacterial strains
EP3638271B1 (en) 2017-06-14 2020-10-14 4D Pharma Research Limited Compositions comprising bacterial strains
HUE052258T2 (en) 2017-06-14 2021-04-28 4D Pharma Res Ltd Compositions comprising a bacterial strain of the genus megasphaera and uses thereof
US11077179B2 (en) 2017-08-10 2021-08-03 Epicgenetics, Inc. Method for treating fibromyalgia and chronic fatigue syndrome
EP3735265A4 (en) * 2018-01-03 2021-11-10 Qu Biologics Inc. Innate targeting of adoptive cellular therapies
WO2020010254A1 (en) * 2018-07-03 2020-01-09 Artizan Biosciences Compositions and methods for treating inflammatory bowel disease
EP3990000A1 (en) * 2019-06-28 2022-05-04 Nantcell, Inc. Pharmaceutical compositions to enhance phagocytosis without inflammation
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN116875516B (en) * 2023-09-06 2023-12-08 上海上药信谊药厂有限公司 Bifidobacterium adolescentis BA-3 and its application in resisting aging, oxidation and inflammation

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928565A (en) 1971-10-19 1975-12-23 Yuzuru Homma Pharmaceutical preparation of pseudomonas aeruginosa bacterial component possessing anti-tumor and anti-infection properties
US4326452A (en) 1977-10-24 1982-04-27 Matsushita Electric Industrial Co., Ltd. Fluid diverting assembly
JPS5946493B2 (en) 1978-03-31 1984-11-13 株式会社三和化学研究所 Antitumor agent containing a mixture of different types of dead bacteria as an active ingredient
JPS56108716A (en) 1980-01-30 1981-08-28 Sanwa Kagaku Kenkyusho:Kk Antiviral agent containing different kind dead cell mixture as effective component
JPS5839624A (en) 1981-09-02 1983-03-08 Meiji Seika Kaisha Ltd Antitumor agent
JPS6012071A (en) 1983-06-30 1985-01-22 東レ株式会社 Body fluid treating agent having anti-tumor action
US4880626A (en) 1985-01-18 1989-11-14 Mcmichael John Immunotherapeutic methods and compositions for the treatment of diseases of viral origin, including acquired immune deficiency syndrome
FR2683529B1 (en) 1991-11-12 1994-02-04 Bretagne Occidentale Universite PHARMACEUTICAL COMPOUNDS GEM-DIPHOSPHONATES ANALOGUE OF CIS-PLATINUM.
US5292513A (en) 1992-05-18 1994-03-08 Anthony G. Gristina Method for nonspecific cellular immune stimulation
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
GB9406301D0 (en) 1994-03-30 1994-05-25 Univ London Immunotherapeutic agent and its use
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
WO1997036614A1 (en) * 1996-03-29 1997-10-09 Terman David S Polymerized staphylococcal protein a for treatment of diseases
US6348586B1 (en) 1996-07-25 2002-02-19 The Trustees Of Columbia University In The City Of New York Unique associated Kaposi's sarcoma virus sequences and uses thereof
US20020128240A1 (en) 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6028060A (en) 1997-01-29 2000-02-22 Vanderbilt University Treatment of chronic inflammatory diseases with CM101/GBS toxin
ES2368824T3 (en) 1998-03-27 2011-11-22 Oregon Health & Science University VITAMIN D AND ITS ANALOGS IN THE TREATMENT OF TUMORS AND OTHER HYPERPROLIFERATIVE DISORDERS.
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
TWI306760B (en) 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
US7118740B1 (en) 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
CA2427572A1 (en) * 2000-11-01 2002-05-10 The Regents Of The University Of California Immunomodulatory peptides derived from heat shock proteins and uses thereof
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
FR2822071B1 (en) 2001-03-15 2005-07-01 Pf Medicament USE OF A MEMBRANE FRACTION OF GRAM NEGATIVE BACTERIA TO INDUCE THE MATURATION OF DENDRITIC CELLS
DK2027873T3 (en) * 2001-07-02 2015-11-09 Zoetis Services Llc Single Dose Vaccination with Mycoplasma hyopneumoniae
JP4859341B2 (en) 2001-07-19 2012-01-25 昭 林 Human immunotherapy
WO2003013558A1 (en) * 2001-07-30 2003-02-20 Claudio De Simone Treatment of radiation-induced diarrhea with probiotics
EP1281767A3 (en) 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
AU2002353366A1 (en) 2001-12-10 2003-06-23 Bakulesh Mafatlal Khamar The process of manufacturing a pharmaceutical composition useful for management of cancer
WO2003063593A1 (en) 2002-01-28 2003-08-07 Vion Pharmaceuticals, Inc. Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent
JP2006502964A (en) 2002-02-06 2006-01-26 ジョンズ ホプキンス ユニバーシティ スクール オブ メディシン Methods and compositions for targeting a systemic immune response against a specific organ or tissue
US20060127411A1 (en) 2002-02-15 2006-06-15 Bioagency Ag Immune -modulating peptide made of s.aureus enterotoxin b
EP1511768B1 (en) 2002-06-11 2007-04-11 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
JP4618970B2 (en) 2002-08-02 2011-01-26 マルホ株式会社 Anal pressure reduction external preparation
IL152127A0 (en) 2002-10-06 2003-05-29 Bio Balance Corp Probiotic compositions for the treatment of inflammatory bowel disease
US7179460B2 (en) * 2002-12-05 2007-02-20 Danisco A/S Bacterial composition and its use
WO2004064717A2 (en) * 2003-01-21 2004-08-05 Yeda Research And Development Co. Ltd. Cop 1 for treatment of inflammatory bowel diseases
PE20050068A1 (en) 2003-02-06 2005-03-11 Novartis Ag 2-CYANOPYRROLOPYRIMIDINES AS INHIBITORS OF CATEPSIN S
GB0307026D0 (en) 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
NZ542866A (en) * 2003-04-23 2009-07-31 Medarex Inc Compositions and methods for the therapy of inflammatory bowel disease
CN1332018C (en) * 2003-11-03 2007-08-15 安徽龙科马生物制药有限责任公司 Freezing dried mycobatctericsis preparation and its preparing method and use
US20050100559A1 (en) * 2003-11-07 2005-05-12 The Procter & Gamble Company Stabilized compositions comprising a probiotic
US7413728B2 (en) * 2003-11-14 2008-08-19 Ucl Biomedica Plc Immune modulator
US20050175630A1 (en) 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
EP1586330A1 (en) 2004-04-16 2005-10-19 Georg-August-Universität Göttingen Vaccination against malignant melanoma
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8034359B2 (en) * 2004-06-07 2011-10-11 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to cancers
NZ586338A (en) * 2004-06-07 2012-02-24 Qu Biolog Inc Bacterial compositions for the treatment of cancer
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8029777B2 (en) * 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
CN101048181A (en) * 2004-08-13 2007-10-03 巴里·J·马沙尔 Bacteria delivering system
JP5234445B2 (en) 2004-10-05 2013-07-10 源一郎 杣 Drug
US8092793B2 (en) 2004-12-15 2012-01-10 Qingdao East Sea Pharmaceuticals, Ltd. Treating inflammatory bowel disease with live bacteria
CA2531261A1 (en) * 2005-12-21 2007-06-21 Institut Pasteur Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
JP2009522311A (en) 2005-12-29 2009-06-11 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド Methods for regulating intestinal flora in animals
CA2652559A1 (en) * 2006-05-18 2007-11-29 Biobalance Llc Biotherapeutic compositions and uses thereof
CN101563100B (en) * 2006-08-28 2013-08-07 李季男 Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
NZ715882A (en) * 2006-10-27 2017-07-28 Qu Biologics Inc Tissue targeted antigenic activation of the immune response to treat cancers
CA2571805C (en) * 2006-10-27 2018-05-01 Harold David Gunn Tissue targeted antigenic activation of the immune response to cancers
CN101085347B (en) * 2007-06-15 2010-05-19 东南大学 Hepatitis A, hepatitis B and hepatitis E combination vaccine
WO2009013443A1 (en) * 2007-07-23 2009-01-29 Vaccine Research International Plc Inactivated staphylococcal whole-cell vaccine
WO2009021977A1 (en) 2007-08-16 2009-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Human specific escherichia coli strains
HUP0700552A2 (en) * 2007-08-27 2009-03-30 Janos Dr Feher Method and composition inhibiting inflammation
EP2085466A1 (en) * 2008-01-29 2009-08-05 AEterna Zentaris GmbH Non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages, process of manufacturing and uses thereof
WO2010068413A1 (en) * 2008-11-25 2010-06-17 Emergent Product Development Gaithersburg Inc. Chlamydia vaccine comprising htra polypeptides
DK2403510T3 (en) 2009-03-05 2020-03-23 Probiotical Spa BACKGROUND STREAMS WITH A HIGH ANTI-INFLAMMATORY ACTIVITY
KR102157718B1 (en) 2010-07-26 2020-09-18 큐 바이올로직스 인코포레이티드 Immunogenic anti-inflammatory compositions
JP6012071B2 (en) 2012-12-03 2016-10-25 太平洋セメント株式会社 Chlorine bypass exhaust gas treatment method

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRAAT HENRI ET AL: "Prevention of experimental colitis by parenteral administration of a pathogen-derived immunomodulatory molecule", GUT, vol. 56, no. 3, March 2007 (2007-03-01), pages 351 - 357, XP008167394, ISSN: 0017-5749 *
KRUIS W ET AL: "Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis", ALIMENTARY PHARMACOLOGY AND THERAPEUTICS, vol. 11, no. 5, 1997, pages 853 - 858, XP002720258, ISSN: 0269-2813 *
MARKS D J ET AL: "Defective acute inflammation in Crohn's disease: a clinical investigation", THE LANCET, ELSEVIER, AMSTERDAM, NL, vol. 367, no. 9511, 25 February 2006 (2006-02-25), pages 668 - 678, XP025093731, ISSN: 0140-6736, [retrieved on 20060225], DOI: 10.1016/S0140-6736(06)68265-2 *
TORRES JAVIER F ET AL: "Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters", INFECTION AND IMMUNITY, vol. 63, no. 12, 1995, pages 4619 - 4627, XP002720257, ISSN: 0019-9567 *

Also Published As

Publication number Publication date
EP4324526A2 (en) 2024-02-21
AU2011284737A8 (en) 2016-08-04
IL277110A (en) 2020-10-29
CN103140238A (en) 2013-06-05
CN103140238B (en) 2016-03-16
CN105797145A (en) 2016-07-27
AU2021203627A1 (en) 2021-07-01
EP3235506B1 (en) 2023-12-06
IL224048B (en) 2020-09-30
KR20130132762A (en) 2013-12-05
ES2645509T3 (en) 2017-12-05
RU2013108248A (en) 2014-09-10
EP3235506C0 (en) 2023-12-06
JP2017149751A (en) 2017-08-31
MY188328A (en) 2021-11-30
KR20180115354A (en) 2018-10-22
NZ606490A (en) 2015-04-24
RU2581922C2 (en) 2016-04-20
RU2016106134A3 (en) 2019-07-17
AU2011284737B2 (en) 2016-07-07
JP6129378B2 (en) 2017-05-17
US10130692B2 (en) 2018-11-20
AU2016238866B2 (en) 2018-07-19
SG187201A1 (en) 2013-02-28
JP5923501B2 (en) 2016-05-24
EP2598165B1 (en) 2017-09-20
JP2021088568A (en) 2021-06-10
RU2722357C2 (en) 2020-05-29
ES2971415T3 (en) 2024-06-05
SG10201604175XA (en) 2016-07-28
AU2016238866A1 (en) 2016-10-27
DK2598165T3 (en) 2017-10-16
MX345240B (en) 2017-01-23
AU2011284737A1 (en) 2013-02-28
US20120258135A1 (en) 2012-10-11
JP2019070040A (en) 2019-05-09
WO2012012874A1 (en) 2012-02-02
EP2598165A1 (en) 2013-06-05
IL277110B (en) 2022-10-01
JP2016193902A (en) 2016-11-17
AU2018250480B2 (en) 2021-03-04
KR101916853B1 (en) 2018-11-09
AU2018250480A1 (en) 2018-11-15
EP3235506A1 (en) 2017-10-25
PL2598165T3 (en) 2018-02-28
CA2804709A1 (en) 2012-02-02
JP6471188B2 (en) 2019-02-13
MX2013001032A (en) 2013-06-05
KR102157718B1 (en) 2020-09-18
IL277110B2 (en) 2023-02-01
EP2598165A4 (en) 2014-03-26
NZ702796A (en) 2017-03-31
JP2013532665A (en) 2013-08-19
RU2016106134A (en) 2018-11-22

Similar Documents

Publication Publication Date Title
EP4324526A3 (en) Immunogenic anti-inflammatory compositions
EP3725328A3 (en) Novel adjuvant compositions
PH12021550756A1 (en) Compositions and methods for treating and/or preventing cardiovascular disease
AR118199A2 (en) IMMUNOGENIC COMPOSITIONS OF NON-LIPID NON-PIRUVILATED VARIANTS OF ORF2086 ANTIGENS FROM NEISSERIA MENINGITIDIS, POLIPEPTIDES, NUCLEOTIDE SEQUENCES AND PLASMIDS
MX2013004817A (en) Inflammatory disease.
MY165831A (en) Methods of reducing virucidal activity in pcv-2 compositions and pcv-2 compositions with a improved immunogenicity
GEP20166457B (en) Low-oil pharmaceutical emulsion compositions comprising progestogen
EP4417261A3 (en) Bacteriotherapy
MX2013008850A (en) Compositions and methods for treating cardiovascular diseases.
EP3263128A3 (en) Compositions for immunising against staphylococcus aureus
EP2561855A3 (en) Method for chemically modifying the internal region of a hair shaft
EP2574170A4 (en) Immunostimulatory and vaccine compositions
EP3111924A3 (en) Oral care compositions
MX341918B (en) Liposome formulation suitable for treating or preventing tuberculosis.
NZ599521A (en) Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease
BRPI0918226A2 (en) immunogenic composition, method for producing an immunogenic composition, method for eliciting an immune response against neisseria, use of the immunogenic composition, and vaccine
CY1122827T1 (en) DELIVERY OF CHOLESTERYL ESTER TO STEROIDATED TISSUES
EP4249057A3 (en) Betulin-containing birch bark extracts and their formulation
CY1119704T1 (en) Trisaccharide derivatives, and their use as immunosuppressants
WO2015041710A8 (en) Ospa fusion protein for vaccination against lyme disease
EP3257525A3 (en) Vaccine compositions
CO6680627A2 (en) Immunogenic anti-inflammatory compositions
MX2013005624A (en) Novel indolizine derivatives, and preparation and therapeutic use thereof.
MX2013002841A (en) Immunogenic compositions.
UA104138C2 (en) Novel adjuvant compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 2598165

Country of ref document: EP

Kind code of ref document: P

Ref document number: 3235506

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: APP_45634/2024

Effective date: 20240806